Association between Immune Checkpoint Inhibitor Treatment Outcomes and Body Composition Factors in Metastatic Renal Cell Carcinoma Patients

• Published in: Cancers Vol. 15; no. 23; p. 5591
• Main Authors: Takei, Kohei, Kijima, Toshiki, Okubo, Naoya, Kurashina, Ryo, Kokubun, Hidetoshi, Uematsu, Toshitaka, Betsunoh, Hironori, Yashi, Masahiro, Kamai, Takao
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26.11.2023
• Subjects: Antimitotic agents; Antineoplastic agents; Biomarkers; Body composition; body composition-related biomarker; Body mass index; Carcinoma, Renal cell; Computed tomography; Disease control; Histology; Immune checkpoint inhibitors; Immune system; Kidney cancer; Kinases; Lymphocytes; Medical prognosis; Medical records; Medical research; Medicine, Experimental; Metastases; Metastasis; Muscles; Musculoskeletal system; Overweight; Patient outcomes; Physiological aspects; Prognosis; Proteins; Quality of life; Renal cell carcinoma; Sarcopenia; Skeletal muscle; Therapeutic applications; Vertebrae; body composition-related biomarker; renal cell carcinoma; immune checkpoint inhibitors; sarcopenia
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15235591

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic renal cell carcinoma (mRCC); however, validating body composition-related biomarkers for their efficacy remains incomplete. We evaluated the association between body composition-related markers and the prognosis of patients with mRCC who received ICI-based first-line therapies. We retrospectively investigated 60 patients with mRCC who underwent ICI-based therapy as their first-line treatment between 2019 and 2023. Body composition variables, including skeletal muscle, subcutaneous fat, and visceral fat indices, were calculated using baseline computed tomography scans. Sarcopenia was defined according to sex-specific cut-off values of the skeletal mass index. The associations between body composition indices and objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were evaluated. Patients with sarcopenia had lower ORR and DCR than those without sarcopenia (33.3% vs. 61.1%, = 0.0436 and 52.4% vs. 94.4%, = 0.0024, respectively). Patients with sarcopenia had a significantly shorter median PFS (14 months vs. not reached, = 0.0020) and OS (21 months vs. not reached, = 0.0023) than patients without sarcopenia did. Sarcopenia was a significant predictor of PFS (hazard ratio [HR], 4.31; 95% confidence interval [CI], 1.65-14.8; = 0.0018) and OS (HR, 5.44; 95% CI, 1.83-23.4; = 0.0013) along with poor IMDC risk. No association was found between the subcutaneous, visceral, and total fat indices and the therapeutic effect of ICI-based therapy. Sarcopenia was associated with a lower response and shorter survival rates in patients with mRCC who received first-line ICI-based therapy.